Lovastatin

Pricing Availability   Qty
Description: Potent HMG-CoA reductase inhibitor
Alternative Names: Mevinolin
Chemical Name: (2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate
Purity: ≥97% (HPLC)
Datasheet
Citations (11)
Reviews (1)
Literature (2)

Biological Activity for Lovastatin

Lovastatin is a potent, competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM) therefore decreases cholesterol biosynthesis, in vitro and in vivo. Indirectly inhibits Rho-GTPase activity by depleting intracellular pool of isoprene residues. Decreases CDK2, 4, 6 and cyclin E levels and induces G1 arrest and apoptosis in tumor cell lines in vitro. Inactive lactam prodrug of lovastatin hydroxy acid, naturally bioactivated in vivo following oral administration.

Compound Libraries for Lovastatin

Lovastatin is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.

Technical Data for Lovastatin

M. Wt 404.54
Formula C24H36O5
Storage Store at +4°C
Purity ≥97% (HPLC)
CAS Number 75330-75-5
PubChem ID 53232
InChI Key PCZOHLXUXFIOCF-BXMDZJJMSA-N
Smiles [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Lovastatin

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
ethanol 20.23 50 with gentle warming
DMSO 40.45 100

Preparing Stock Solutions for Lovastatin

The following data is based on the product molecular weight 404.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.47 mL 12.36 mL 24.72 mL
5 mM 0.49 mL 2.47 mL 4.94 mL
10 mM 0.25 mL 1.24 mL 2.47 mL
50 mM 0.05 mL 0.25 mL 0.49 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for Lovastatin

References are publications that support the biological activity of the product.

Alberts (1988) Discovery, biochemistry and biology of lovas. Am.J.Cardiol. 62 10J PMID: 3055919

Alberts et al (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc.Natl.Acad.Sci.U.S.A. 77 3957 PMID: 6933445

Park et al (1999) Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res. 19 3133 PMID: 10652602

Ziegler et al (2017) Rho inhibition by lovas. affects apoptosis and DSB repair of primary human lung cells in vitro and lung tissue in vivo following fractionated irradiation. Cell Death Dis. 8 e2978 PMID: 28796249


If you know of a relevant reference for Lovastatin, please let us know.

View Related Products by Target

View Related Products by Product Action

View all HMG-CoA Reductase Inhibitors

Keywords: Lovastatin, Lovastatin supplier, HMG-CoA, reductases, inhibitors, inhibits, statins, Mevinolin, Reductase, 1530, Tocris Bioscience

⚠ WARNING: This product can expose you to chemicals including Lovastatin, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information, go to www.P65Warnings.ca.gov

11 Citations for Lovastatin

Citations are publications that use Tocris products. Selected citations for Lovastatin include:

Buchovecky et al (2013) A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet 45 1013 PMID: 23892605

Kah et al (2012) Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 28 1077 PMID: 22710979

Park et al (2016) Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 17 914 PMID: 27270401

Leznicki et al (2018) Expansion of DUB functionality generated by alternative isoforms - USP35, a case study. J Cell Sci 131 PMID: 29685892


Do you know of a great paper that uses Lovastatin from Tocris? Please let us know.

Reviews for Lovastatin

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Lovastatin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


GTPase inhibitor.
By Mengxi Lv on 03/26/2018
Assay Type: In Vitro
Species: Other
Cell Line/Tissue: chondrocyte

used as Rho GTPase activity inhibitor

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Metabolism Research Product Guide

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.